SCHEMBL5007422

SCHEMBL5007422

Cc1noc(C2CC(N3CCC(C(=O)O)CC3)C2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.43
CCR5 P51681 1/20 0.40
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HSD11B1 P28845 4/20 0.39
CHRM2 P08172 1/20 0.38
OGA O60502 1/20 0.37
FAAH O00519 1/20 0.35
TSHR P16473 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22628949 0.81 EPHX2 (0.43) EPHX2CCR5HSD11B1CHRM2FAAH
SCHEMBL22628906 0.80 EPHX2 (0.44) EPHX2CCR5KDM4EUSP2HPGD
SCHEMBL22629018 0.77 KDM1A (0.44) EPHX2CCR5HSD11B1CHRM2
SCHEMBL22629468 0.73 KDM4E (0.53) KDM4EUSP2HPGDNPSR1HSD17B10
SCHEMBL5004068 0.72 CCR5 (0.45) EPHX2CCR5KDM4EHSD17B10HSD11B1
SCHEMBL5634920 0.72 EPHX2 (0.57) EPHX2CCR5HSD11B1CHRM2OGA
Oxalic Acid SCHEMBL10419848 0.71 HSD11B1 (0.50) EPHX2CCR5HSD11B1CHRM2OGA
Oxalic Acid SCHEMBL10419846 0.71 HSD11B1 (0.50) EPHX2CCR5HSD11B1CHRM2OGA
SCHEMBL8872442 0.70 CHRM2 (0.46) EPHX2CCR5KDM4EUSP2HPGD
SCHEMBL20292116 0.70 EPHX2 (0.43) EPHX2CCR5HSD11B1CHRM2OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 EPHX2 2616/4885CCR5 496/4885KDM4E 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.